Techniclone Corp.: The Tustin cancer therapeutics company...

Techniclone Corp.: The Tustin cancer therapeutics company said it lost $1.4 million, or 7 cents a share, for the third quarter ended Jan. 31, compared with a net loss of $890,271, or 5 cents a share, for the same period a year ago. Revenue increased 40% to $59,962 from $42,751. For the first nine months, the company lost $3.9 million, or 18 cents a share, compared to a net loss of $1.9 million, or 11 cents a share, for the same period of 1996. Revenue advanced to $232,307 from $42,772. The company said the increased losses were due primarily to expansion of clinical trial activities, as well as facilities expansion and management additions.